New approaches to treatment of anemia of chronic disease

Authors

  • A. V. Budnevskiy 1 2 N.N. Burdenko Voronezh State Medical University, Voronezh 394000, Russia
  • Evgeniy S. Ovsyannikov 1 2 N.N. Burdenko Voronezh State Medical University, Voronezh 394000, Russia
  • E. V. Voronina Department of the Obstetrics and Gynecology, Institute of Advanced Postgraduate Education at the N.N. Burdenko Voronezh State Medical University, 394000, Voronezh, Russia
  • N. B. Labzhaniya 1 2 N.N. Burdenko Voronezh State Medical University, Voronezh 394000, Russia
  • Yu. G. Zhusina 1 2 N.N. Burdenko Voronezh State Medical University, Voronezh 394000, Russia

DOI:

https://doi.org/10.25557/0031-2991.2018.03.106-112

Keywords:

anemia of chronic disease, hepcidin, erythroferrone, Gs-heparins

Abstract

Anemia of chronic disease is often associated with multiple chronic infectious diseases (infectious endocarditis, osteomyelitis, tuberculosis), cancer, rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, vasculitis), and chronic renal failure. The pathogenesis of this anemia is rather complex, diverse, and poorly understood. Hepcidin is an important peptide that regulates iron absorption in the intestine. Many upstream and downstream signaling pathways regulate expression of hepcidin. A genetic defect in one of them may lead to deficiency, excess or redistribution of iron in the body. Timely detection and correction of anemia can improve the quality of life and survival of patients. Modern methods for correction of anemia of chronic disease are usually limited to the uncontrolled use of iron supplements. The recombinant erythropoietin treatment is most commonly used in patients with chronic renal failure. These therapeutic tactics are usually explained by depression of erythropoietin synthesis by proinflammatory cytokines. Currently, a number of drugs is being developed, which inhibit hepcidin synthesis directly or indirectly by regulating expression of hepcidin inhibitors and stimulators. Some drugs have already been approved for clinical use and can be successfully used for treatment of anemia. In this review, we presented a new, pathogenetically well-grounded approach to the treatment of anemia of chronic disease.

Downloads

Published

2018-10-05

Issue

Section

Reviews

How to Cite

[1]
2018. New approaches to treatment of anemia of chronic disease. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 62, 3 (Oct. 2018), 106–112. DOI:https://doi.org/10.25557/0031-2991.2018.03.106-112.